The 7777.T stock of 3-D Matrix, Ltd. is trading at JPY 645.00, down 5.15% intraday as investors set positions ahead of the company’s earnings announcement scheduled for 12 March 2026. Volume is elevated at 8,226,400 shares, above the 50-day average of 7,817,562, signaling active trading. Key near-term drivers are expected to be reported EPS, guidance on PuraMatrix sales, and commentary on R&D spending. We examine financial ratios, technicals, Meyka AI forecasts, and realistic price targets to frame what the report could mean for JPX-listed 3-D Matrix in Japan.

7777.T stock: what the intraday move shows

Today’s price action shows 7777.T stock opening at JPY 666.00 and hitting a day low of JPY 626.00 and a high of JPY 668.00. The intraday decline of JPY -35.00 (-5.15%) reflects profit-taking after recent gains (YTD +91.74%) and higher-than-average volume. One clear claim: traders are reducing exposure ahead of earnings on 12 March 2026. This short-term volatility increases how traders price forward guidance and R&D updates for the medical devices firm.

7777.T stock: earnings and fundamentals to watch

The immediate focus for 7777.T stock is the earnings announcement on 12 March 2026 and how management addresses sales of PuraMatrix and cell-therapy contracts. Key reported metrics to watch are EPS (latest reported EPS is -3.26) and operating margin trends. One claim per sentence: profitability remains fragile; last reported PE shown on summary is -213.50 reflecting negative trailing EPS. Management commentary on revenue growth and R&D guidance will determine whether sentiment stabilizes or weakens further.

7777.T stock: valuation, key ratios and analyst context

On valuation, 7777.T stock shows stretched multiples versus peers: price-to-sales is 9.88, and price-to-book is 20.62. One claim: current ratios are conservative on balance-sheet strength, with a current ratio of 4.00 and cash per share JPY 13.48. The company’s market cap is JPY 83,667,907,656.00. External analyst consensus is sparse, and company rating data dated 06 Mar 2026 lists an overall rating of C (Sell) from one provider. Contrast this with company growth metrics, where revenue and EPS growth showed material year-over-year gains in FY 2024.

7777.T stock: technicals and trading signals

Technical indicators show momentum but short-term caution for 7777.T stock. RSI is 67.35, MACD histogram +6.05, and ADX 49.67, indicating a strong trend but an overbought tilt. Bollinger middle band sits near JPY 581.60 while the upper band is JPY 718.71. One claim: trading volumes are elevated with relative volume 1.10, which supports the intraday move as meaningful, not noise. Traders should watch the JPY 626.00 support and the JPY 668.00 intraday resistance for confirmation.

7777.T stock: risks, opportunities and sector context

Risks for 7777.T stock include continued negative EPS, long inventory cycles (days of inventory 339.61) and interest coverage at -5.73, which signal sensitivity to higher financing costs. One claim: opportunity stems from PuraMatrix adoption in regenerative medicine and steady R&D investment (R&D/revenue ~6.26%). In the broader Healthcare sector on the JPX, peers trade at average PE near 24.35, making 3-D Matrix’s premium PS and PB ratios notable. Sector performance is modest YTD; healthcare YTD is +3.41%, so company-specific catalysts will drive direction.

7777.T stock: Meyka AI grade and model forecasts

Meyka AI rates 7777.T with a score out of 100: 74.98, Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly JPY 574.77 and yearly JPY 214.86. Relative to today’s price JPY 645.00, the model implies a near-term move of -10.89% to monthly forecast and -66.62% to the one-year projection. Forecasts are model-based projections and not guarantees. We include this grade and model to show a data-driven downside scenario versus a constructive fundamental case.

Final Thoughts

Key takeaways for 7777.T stock: 3-D Matrix trades at JPY 645.00 on the JPX with elevated intraday volume and a -5.15% move as investors position ahead of earnings on 12 March 2026. Financials show strong balance-sheet liquidity (current ratio 4.00) but negative EPS (-3.26) and stretched valuation (PB 20.62, PS 9.88). Technical indicators show a strong trend (ADX 49.67) but an overbought RSI (67.35). Meyka AI rates 7777.T with a score out of 100 at 74.98 (B+, BUY) reflecting growth and sector comparisons, while the model projects a monthly price of JPY 574.77 (implied -10.89%) and a one-year figure of JPY 214.86 (implied -66.62%). Investors should treat today’s gap lower as a volatility event ahead of guidance. If management confirms accelerating PuraMatrix revenue and tighter inventory cycles, upside toward a near-term analyst price target around JPY 700.00 could be warranted. Conversely, weak guidance could validate the model’s downside scenario. Use earnings as the decisive trigger, size positions to risk tolerance, and consult the company’s JPX filings and our platform for real-time updates. Meyka AI-powered market analysis platform provides these model-based views; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.